Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 5/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8819946 | 0.91 | BTK (0.43) | BTKSRC | |
| Tert-Butyl Formate SCHEMBL28231423 | 0.91 | BTK (0.48) | BTKLCKSRC | |
| SCHEMBL5250649 | 0.89 | TNK2 (0.47) | BTKLCKSRCTNK2TEK | |
| SCHEMBL409545 | 0.88 | HTR6 (0.43) | BTKSRCTNK2 | |
| SCHEMBL23847508 | 0.88 | TNK2 (0.48) | BTKLCKSRCTNK2TEK | |
| SCHEMBL8819702 | 0.85 | EGFR (0.41) | BTKLCKSRCTNK2 | |
| SCHEMBL21044835 | 0.82 | BTK (0.73) | BTKTNK2 | |
| SCHEMBL23834462 | 0.81 | BTK (0.45) | BTKLCKTNK2 | |
| SCHEMBL22710626 | 0.80 | BTK (0.56) | BTKLCKSRC | |
| SCHEMBL8820010 | 0.79 | EGFR (0.43) | SRCTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | SHENZHEN TARGETRX, INC. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen TargetRx. Inc. (CN) | 2021-03-11 | — | — | US | disclosed |
| EP-3492471-B1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | SHENZHEN TARGETRX INC (CN) | 2020-12-02 | — | — | EP | disclosed |
| US-10435409-B2 | Process for the preparation of ibrutinib | SHILPA MEDICARE LIMITED | 2019-10-08 | — | — | US | disclosed |
| CN-109851620-A | For inhibiting the condensed-bicyclic class compound of tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2019-06-07 | — | — | CN | disclosed |
| EP-3492471-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | Shenzhen Targetrx, Inc. (CN) | 2019-06-05 | — | — | EP | disclosed |
| CN-108368119-B | Fused Bicyclic Compounds for Inhibiting Tyrosine Kinase Activity | 深圳市塔吉瑞生物医药有限公司 | 2019-04-23 | — | — | CN | disclosed |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2019-02-07 | — | — | US | disclosed |
| WO-2017134588-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | SHILPA MEDICARE LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186578-B2 | Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors | LCK, BTK, BRAF | BTK 2/4885LCK 1/4885SRC 15/4885 |
| US-20190040069-A1 | PROCESS FOR THE PREPARATION OF IBRUTINIB | BTK, SYK, JAK1 | BTK 1/4885LCK 45/4885SRC 90/4885 |
| US-20210070758-A1 | FUSED BICYCLIC COMPOUND FOR INHIBITING ACTIVITY OF TYROSINE KINASE | LCK, BTK, LYN | BTK 2/4885LCK 1/4885SRC 4/4885 |
| US-10435409-B2 | Process for the preparation of ibrutinib | BTK, SYK, JAK1 | BTK 1/4885LCK 58/4885SRC 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.